5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancergastroesophageal junction adenocarcinomaRecruitingPhase 32026-09-11NCT06764875
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorderRecruitingPhase 32026-08-10NCT06731478
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32026-06-17NCT04961996
Effect of Continuous Prolonged Prone Position Versus Intermittent Daily Prone Position in ARDSRespiration Disorders, adult acute respiratory distress syndrome, lung disorder, respiratory failure, respiratory system disorderRecruitingNot applicable2026-05-18NCT06854627
EULAT Eradicate GBCBiliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, cholelithiasis, gallbladder disorder, gallbladder neoplasm, neoplasmRecruitingNot stated2026-02-18NCT06192719